Dapagliflozin for Heart Failure: SGLT2 Inhibitor Trends & Research

Okay,here’s a breakdown of ‍the reference‍ list⁢ entries you provided,extracting ⁢key details from ⁣each:

Reference 37:

* Authors: Ronco,C; Haapio,M; House,AA; Anavekar,N; Bellomo,R
* Title: Cardiorenal syndrome
* ‍ Journal: J Am Coll Cardiol
* DOI: 10.1016/j.jacc.2008.07.051
* Volume: 52
*⁤ ⁣ Issue: 19
* Pages: ‍ 1527-39
* Year: 2008

Reference 38:

* ⁣ Author: Brenner BM
* Title: Hemodynamically mediated glomerular injury and the progressive nature of kidney disease
* Journal: Kidney Int
* DOI: 10.1038/ki.1983.72
* ⁣ volume: 23
* ‍ Issue: 4
* ⁢ Pages: ‍647-55
* Year: 1983

Reference ⁣39:

* Authors: Pitt⁣ B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al.
* Title: Spironolactone for heart failure with preserved ejection fraction
* Journal: ⁣N Engl J Med
* ⁣ Volume: 370
* Issue: 15
* Pages: 1383-92
* ⁤ Year: 2014

Observations:

* ⁢ ‍ the references are formatted in a standard bibliographic style.
* Each entry includes author(s), title, journal, and publication details (volume, issue, pages, year).
* The entries also ⁤include links⁤ to ⁤various databases (google Scholar, PubMed, CAS, Article) for further⁣ information.
* The⁣ rel="nofollow noopener" ⁤ attribute on the links⁤ suggests ‍that these are external links and the website owner doesn’t necessarily endorse the content.
* The data-track attributes indicate that clicks on these links are⁤ being tracked for analytics purposes.